LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $18,600 | +28.2% | 12,400 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $14,508 | +3.6% | 12,400 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $14,000 | -30.0% | 12,400 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $20,000 | +5.3% | 12,400 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $19,000 | -36.7% | 12,400 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $30,000 | -36.2% | 12,400 | -32.6% | 0.00% | -33.3% |
| Q3 2021 | $47,000 | -29.9% | 18,400 | -21.2% | 0.00% | -40.0% |
| Q2 2021 | $67,000 | +45.7% | 23,360 | +18.8% | 0.01% | +25.0% |
| Q1 2021 | $46,000 | +70.4% | 19,670 | +24.9% | 0.00% | +100.0% |
| Q4 2020 | $27,000 | +92.9% | 15,750 | +6.8% | 0.00% | +100.0% |
| Q3 2020 | $14,000 | 0.0% | 14,750 | -8.7% | 0.00% | 0.0% |
| Q2 2020 | $14,000 | -6.7% | 16,150 | -19.9% | 0.00% | -50.0% |
| Q1 2020 | $15,000 | -16.7% | 20,150 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $18,000 | -47.1% | 20,150 | -42.7% | 0.00% | -50.0% |
| Q3 2019 | $34,000 | – | 35,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Defender Capital, LLC. | 4,735,990 | $8,335,000 | 3.63% |
| BROADWOOD CAPITAL INC | 34,005,379 | $59,849,000 | 3.55% |
| Prescott General Partners LLC | 1,851,851 | $3,259,000 | 0.14% |
| Strategic Wealth Investment Group, LLC | 66,917 | $118,000 | 0.07% |
| Laidlaw Wealth Management LLC | 170,658 | $300,000 | 0.06% |
| Humankind Investments LLC | 26,737 | $47,000 | 0.05% |
| DAFNA Capital Management LLC | 80,000 | $141,000 | 0.04% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $79,000 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 680,839 | $1,198,000 | 0.02% |
| Allegheny Financial Group LTD | 20,000 | $35,000 | 0.02% |